RBOT vs. INGN, AVR, LAKE, ZJYL, MLSS, NTRB, SPAI, APT, COCH, and CLGN
Should you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Inogen (INGN), Anteris Technologies Global (AVR), Lakeland Industries (LAKE), Jin Medical International (ZJYL), Milestone Scientific (MLSS), Nutriband (NTRB), Safe Pro Group Inc. Common Stock (SPAI), Alpha Pro Tech (APT), Envoy Medical (COCH), and CollPlant Biotechnologies (CLGN). These companies are all part of the "surgical appliances & supplies" industry.
Vicarious Surgical vs.
Inogen (NASDAQ:INGN) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
In the previous week, Inogen had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for Inogen and 1 mentions for Vicarious Surgical. Inogen's average media sentiment score of 0.30 beat Vicarious Surgical's score of 0.00 indicating that Inogen is being referred to more favorably in the media.
Inogen has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Vicarious Surgical has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.
Vicarious Surgical has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
89.9% of Inogen shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 1.5% of Inogen shares are owned by insiders. Comparatively, 11.7% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Vicarious Surgical has a net margin of 0.00% compared to Inogen's net margin of -15.89%. Inogen's return on equity of -27.38% beat Vicarious Surgical's return on equity.
Inogen presently has a consensus price target of $7.00, suggesting a potential downside of 0.85%. Vicarious Surgical has a consensus price target of $9.25, suggesting a potential upside of 15.77%. Given Vicarious Surgical's higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Inogen.
Inogen received 381 more outperform votes than Vicarious Surgical when rated by MarketBeat users. Likewise, 68.85% of users gave Inogen an outperform vote while only 32.00% of users gave Vicarious Surgical an outperform vote.
Summary
Inogen beats Vicarious Surgical on 9 of the 15 factors compared between the two stocks.
Get Vicarious Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vicarious Surgical Competitors List
Related Companies and Tools
This page (NYSE:RBOT) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy RBOT Stock Free RBOT Stock Alerts